Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 21

1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment

Date

21 Oct 2023

Session

Poster session 21

Topics

Clinical Research;  Cancer Biology;  Translational Research;  Targeted Therapy;  Molecular Oncology;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

WenFeng Fang

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

W. Fang1, F. Cappuzzo2, J.W. Goldman3, Y. Zhao1, Y. Huang1, I. Anderson4, J. Remon Masip5, W. Li6, M. Xia6, J. Li7, D. James8, L. Styles9, H.L. West10, L. Zhang11

Author affiliations

  • 1 Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, 00144 - Rome/IT
  • 3 Medicine, UCLA Hematology/Oncology Santa Monica, 90404 - Santa Monica/US
  • 4 Medical Oncology, Providence Medical Group, 95403 - Santa Rosa/US
  • 5 Cancer Medicine Department, Gustave Roussy, 94805 - Villejuif/FR
  • 6 Oncology, Akeso Biopharma Inc., 528437 - Zhongshan/CN
  • 7 Oncology, Summit Therapeutics, 94025 - Menlo Park/US
  • 8 Clinical Development, Summit Therapeutics, 940254SB - Menlo Park/US
  • 9 Clinical Development, Summit Therapeutics, 94025 - Menlo Park/US
  • 10 Medical Oncology, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
  • 11 Medical Oncology Dept., Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1504TiP

Background

For patients (pts) with EGFR-mutant NSCLC, upfront treatment with tyrosine kinase inhibitors is standard. Drug resistance remains a challenge and an effective therapy after progression is needed. Ivonescimab (SMT112/AK112) is a novel bispecific antibody that provides dual blockade of PD-1 and VEGF activity. And coengagement of these 2 targets increases affinity to PD-1 by more than 10 fold. Given the correlation between VEGF-A and PD-1 expression in the tumor microenvironment, simultaneous blockade of these 2 targets by ivonescimab may produce enhanced antitumor activity, with an improved safety profile, compared to co-administration of individual anti-PD-(L)1 and an anti-VEGF agents. Phase 2 trial data reported that in 19 pts with EGFR mutated NSCLC who progressed following TKI therapy, the response rate to ivonescimab plus pemetrexed and carboplatin was of 68.4% (13/19) and a tolerable safety profile in the total population (N=83) treated with ivonescimab plus chemotherapy.

Trial design

HARMONi is a randomized, double-blind, multiregional phase 3 trial of ivonescimab or placebo in combination with pemetrexed and carboplatin in pts with locally advanced or metastatic EGFR-mutant NSCLC. 470 pts will be randomized 1:1 and to receive ivonescimab/placebo plus pemetrexed and carboplatin (Q3W, 4 cycles, 21 days per cycle) followed by ivonescimab/placebo plus pemetrexed for maintenance therapy for up to 2 yrs until progression or unacceptable toxicity. The co-primary endpoints are overall survival and progression-free survival assessed by IRC per RECIST v1.1. Secondary endpoints include overall response rate, incidence/severity of adverse events and immunogenicity of ivonescimab. Key eligibility criteria include advanced or metastatic NSq- NSCLC with an activating EGFR mutation, Eastern Cooperative Oncology Group Performance Status 0 or 1 and progression on/following third generation EGFR-TKI. The study will be a multi-national study including United States, Cana, Euroadpe and China.

Clinical trial identification

NCT05184712.

Editorial acknowledgement

Legal entity responsible for the study

Summit Therapeutics and Akeso Biopharma.

Funding

Summit Therapeutics and Akeso Biopharma.

Disclosure

F. Cappuzzo: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, PharmaMar, Mirati, Novocure, Ose, and MSD; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, Mirati, PharmaMar, Novocure, Ose, Galecto and MSD. J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Genentech, Eli Lilly, Janssen, AbbVie, Gritstone; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Eli Lilly; Financial Interests, Institutional, Local PI: Genentech, Janssen, BMS, AbbVie. J. Remon Masip: Financial Interests, Personal, Invited Speaker: Roche, MSD, Boehringer Ingelheim; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca, Ose Immunotherapeutics, BMS, Janssen, Takeda, Sanofi; Financial Interests, Institutional, Invited Speaker: Merck Portugal; Non-Financial Interests, Principal Investigator, PI of PECATI trial in Thymic malignancies endorsed by a grant by MSD: MSD; Non-Financial Interests, Other, Co-PI of APPLE trial (EORTC-1525): AstraZeneca; Non-Financial Interests, Member, Secretary of the Lung Cancer Group at the EORTC: EORTC. W. Li, M. Xia: Financial Interests, Personal, Full or part-time Employment: Akeso. J. Li, D. James, L. Styles: Financial Interests, Personal, Full or part-time Employment: Summit Therapeutics; Financial Interests, Personal, Stocks/Shares: Summit Therapeutics. H.L. West: Financial Interests, Personal, Advisory Role: Summit Therapeutics. L. Zhang: Financial Interests, Institutional, Research Grant, research grant & Trial Chair: AZ; Financial Interests, Institutional, Research Grant: BMS, Roche; Financial Interests, Institutional, Trial Chair: QiLu pharm, Henrui Pharm, Novartis, Hansoh Pharma, China Shiyao Pharma, Kelun Pharm. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.